Abstract：
Patients with extracorporeal membrane oxygenation (ECMO) support do frequently receive broad-spectrum antibiotics, due to the high frequency of infection by multidrug resistant microorganisms. The extracorporeal circuit can alter the pharmacokinetics (PK) of administered drugs, and in the case of antibiotics this may lead to treatment failure. Cefiderocol is a new cephalosporin that exhibits excellent in vitro activity against many multidrug-resistant (MDR) microorganisms, but there is no published data about the modifications of its PK in patients with ECMO support. Herein we report the results of a pharmacokinetic investigation of cefiderocol in a critically ill patient receiving extracorporeal respiratory support.
摘要：
有体外膜氧合（ECMO）支持的患者经常接受广谱抗生素，由于多重耐药微生物感染的频率很高。体外回路可以改变给药药物的药代动力学（PK），在抗生素的情况下，这可能导致治疗失败。头孢地洛是一种新的头孢菌素，对许多多药耐药（MDR）微生物具有优异的体外活性，但目前尚无关于ECMO支持患者PK改变的公开数据.在此，我们报告了接受体外呼吸支持的重症患者中头孢地洛的药代动力学研究结果。
